Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. PLoS One, 3(4), e2043. presented at the 2008 Apr 30. doi:10.1371/journal.pone.0002043. (2008).
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine, 26(22), 2788-95. presented at the 2008 May 23. doi:10.1016/j.vaccine.2008.02.071. (2008).
CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS One, 4(2), e4401. presented at the 2009. doi:10.1371/journal.pone.0004401. (2009).
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One, 5(9), e12873. presented at the 2010 Sep 21. doi:10.1371/journal.pone.0012873. (2010).
Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J Infect Dis, 201(5), 720-9. presented at the 2010 Mar. doi:10.1086/650492. (2010).
Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One, 7(4), e33103. presented at the 2012. doi:10.1371/journal.pone.0033103. (2012).
Acceptability and feasibility of repeated mucosal specimen collection in clinical trial participants in Kenya. PLoS One, 9(10), e110228. presented at the 2014. doi:10.1371/journal.pone.0110228. (2014).
Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya. AIDS Behav, 19(5), 794-801. presented at the 2015 May. doi:10.1007/s10461-014-0958-x. (2015).
Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults. Mol Ther Methods Clin Dev, 3, 16061. presented at the 2016. doi:10.1038/mtm.2016.61. (2016).
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. J Infect Dis, 215(1), 95-104. presented at the 2017 Jan 01. doi:10.1093/infdis/jiw500. (2017).